ArticleScientific reports2026
Comparative analysis and correlation of cancer hotspot proteins and cell markers in tumor-normal adjacent breast and kidney samples using RPPA and LC-MS.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer proteomics is crucial for understanding tumor biology, yet consistent quantification of clinically relevant proteins across analytical platforms remains challenging. Here, we compared Reverse Phase Protein Array (RPPA) and Liquid Chromatography-Mass Spectrometry (LC-MS) using identical lysate aliquots prepared from matched tumor and adjacent normal tissues from breast and kidney cancer patients. We focused on proteins encoded by genes represented in the Ion AmpliSeq Cancer Hotspot Panel v2 and included representative cellular markers. RPPA was applied to the larger sample set, whereas data-dependent, data-independent, and targeted parallel reaction monitoring LC-MS modes were performed on a smaller subset of lysates. RPPA identified tumor-normal differences for several proteins and cell markers, while LC-MS quantified a smaller overlapping subset in the matched samples analyzed by both platforms. Cross-platform comparison showed that agreement was partial and strongly protein dependent: some targets displayed concordant tumor/normal fold changes, whereas others exhibited weak or even opposite-direction changes. Targeted PRM modestly improved agreement for selected discordant proteins, but substantial discrepancies remained. These data indicate that RPPA and LC-MS are not interchangeable for quantifying all targets in this panel, calling for a rather confirmatory approach: concordant findings increase confidence in selected candidate biomarkers, whereas discordant findings identify targets that require cautious interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.